image header

Investor Overview

Investor Overview

ALX Oncology is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. Our lead candidate, ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated proprietary Fc domain. We have developed a new approach to CD47 blockade that is designed to maximize clinical activity and minimize toxicities.

ALX Oncology

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News

Jan 11, 2021

ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2021 Read more

Jan 5, 2021

ALX Oncology to Present at 39th Annual J.P. Morgan Healthcare Conference Read more

Dec 17, 2020

ALX Oncology Added to the NASDAQ Biotechnology Index Read more